Inmune Bio, Inc.
INMBCIK 0001711754 · Biological Products, (No Diagnostic Substances) · Nasdaq
Revenue (TTM)
$153K
+257.1% YoY
Q1 May 2026
Net Income (TTM)
−$46.08M
−9.2% YoY
Q1 May 2026
EPS Diluted (TTM)
−$1.92
+11.8% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-31,190.2%
Q1 May 2026
Net Margin
-30,115.0%
Q1 May 2026
Free Cash Flow (TTM)
−$19.89M
Q1 May 2026
Cash
$24.75M
Q1 May 2026
Total Debt
$12.19M
Q1 May 2026
Shares Outstanding
26.59M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
Low Neutral
Inmune Bio Adopts Third Amended Stock Incentive Plan
The biotech company's board approved an updated equity compensation plan with 9.2 million shares available for employee and director grants.